Dr. Youmin Zhu | Innovative Leadership | Best Researcher Award

Dr. Youmin Zhu | Innovative Leadership | Best Researcher Award

Shanghai AZ Science and Technology Co., Ltd.

Author Profile

Orchid

🌱 Early Academic Pursuits

From the very beginning of his academic journey, Dr. Youmin Zhu demonstrated an exceptional passion for biological sciences. His intellectual curiosity led him to pursue a Ph.D. in biological sciences, where he laid a solid foundation in molecular biology, biotechnology, and pharmacology. During his doctoral years, he cultivated a deep interest in cutting-edge therapeutic strategies, particularly focusing on emerging protein degradation technologies and the role of bioactive peptides. His academic rigor and scientific curiosity propelled him to explore innovative modalities that bridged traditional research with real-world applications in drug and skincare development. These formative experiences not only enriched his technical skills but also instilled a vision to contribute meaningfully to both science and society.

🧪 Professional Endeavors

Now serving as the R&D President and Chief Scientist at Shanghai AZ Science and Technology Co., Ltd., Dr. Zhu has emerged as a visionary leader in the field of biotechnology. Under his guidance, the organization has completed over 20 major R&D projects, encompassing the development of peptide PROTACs-based skincare ingredients, enzymes, and probiotics. These endeavors reflect not only his scientific expertise but also his ability to translate theoretical concepts into commercial and therapeutic innovations.

Dr. Zhu’s strategic direction in the biotechnology sector has turned his company into a powerhouse of innovation, where the fusion of peptide-based therapeutics and skincare science is leading to transformative solutions. His work has bridged academic excellence with industrial application, enabling breakthroughs in precision medicine and advanced cosmeceuticals.

🔬 Contributions and Research Focus

Dr. Zhu’s research focus lies at the intersection of molecular biology, pharmacological innovation, and cosmetic science, with a central emphasis on peptide PROTACs (Proteolysis Targeting Chimeras). His pioneering efforts in this area have highlighted the multi-targeting potential of peptides, their biodegradability, low toxicity, and modular design, all of which present significant advantages over conventional small molecules and antibodies.

One of his most notable contributions is the publication of the article titled “The Peptide PROTAC Modality: A New Strategy for Drug Discovery” in MedComm (2025), an SCI-indexed journal with an impressive impact factor of 10.7. This work has been widely recognized in the scientific community and is already making waves in discussions around next-generation therapeutic strategies. The article has been cited across multiple domains, further demonstrating its relevance and value in ongoing pharmaceutical research.

With a total of over 10 scientific publications, Dr. Zhu has consistently contributed to scholarly literature and advanced dialogue in biotherapeutics. In addition, he holds 18 authorized patents in China, such as Patent No. CN202410445356.X, further underscoring his commitment to translating innovation into intellectual property and practical applications.

🏆 Accolades and Recognition

Dr. Zhu’s groundbreaking work has not gone unnoticed. His scientific and entrepreneurial achievements have earned him recognition within academic, industrial, and international circles. In addition to being a contributing scientist to impactful research, he has also been actively involved in collaborative projects with prestigious institutions including Fudan University, Shanghai Jiao Tong University, and Zhejiang University.

He is also an esteemed member of professional networks such as the Chinese Overseas Alliance and the Chinese Doctoral Alliance, where he continues to contribute to thought leadership and global knowledge exchange.

Furthermore, his work was recently highlighted in a widely circulated WeChat feature and an official PDF document of professional certification, showcasing his influence in both academic and industrial spheres.

🌍 Impact and Influence

Dr. Zhu’s influence extends beyond scientific circles. His work on peptide PROTACs is helping redefine how we understand and treat complex diseases. By leveraging the natural degradation mechanisms of the body through targeted proteolysis, his innovations are creating new avenues for the treatment of conditions previously considered untreatable.

Equally impressive is his impact on precision skincare, where bioengineered peptide-based compounds are providing customized, low-toxicity solutions for skin health. This cross-disciplinary impact, from health to beauty, positions Dr. Zhu as a transformative figure in the biotech and wellness industries.

His articles, particularly those involving collaborative authorship with Yu Dai and Yuncai Tian, have sparked global interest, and the citation of his MedComm article continues to grow. These ripple effects reflect the profound scientific and commercial value of his work.

🌟 Legacy and Future Contributions

As Dr. Zhu continues to push boundaries, the future of peptide-based therapeutics and cosmeceuticals looks increasingly promising. He is paving the way for a new era of precision medicine, where treatments are not only more effective but also safer and more sustainable.

Looking ahead, Dr. Zhu plans to scale his innovations globally and expand his company’s reach into international markets, bringing Chinese biotechnology to the global stage. His future goals include mentoring young scientists, fostering new academic-industry partnerships, and developing a global research ecosystem centered on peptide technologies.

Through his unwavering dedication and strategic foresight, Dr. Youmin Zhu is building a legacy that will inspire a generation of researchers and innovators. His contributions are not only advancing science but also shaping the future of healthcare and skincare for the better. 🌐

The Peptide PROTAC Modality: A New Strategy for Drug Discovery

Authors: Youmin Zhu, Yu Dai, Yuncai Tian
Journal: MedComm
Year: 2025

New Nobel Prize MicroRNA Technology Is Opening up a New Era of Precision Skincare

Authors: Youmin Zhu, Yu Dai, Xiaojing Wang, Shengjie Zhu, Yuncai Tian, Yong Tian
Journal: Advanced Journal of Nursing
Year: 2025

New peptide PROTAC is triggering a revolution in precise targeted skincare

Authors: Youmin Zhu, Yu Dai, Yuncai Tian, Yong Tian
Journal: Preprint (platform not specified)
Year: 2024

Advances in CRISPR/Cas9

Authors: Youmin Zhu, Syed Hassan
Journal: BioMed Research International
Year: 2022

Comparative Transcriptomics Reveals Jasmonic Acid-Associated Metabolism Related to Cotton Fiber Initiation

Authors: Liman Wang, Youmin Zhu, Wenjing Hu, Xueying Zhang, Caiping Cai, Wangzhen Guo
Journal: PLOS ONE
Year: 2015

Prof Maxime Breban | Prix du meilleur article de rechercher | Best Research Article Award

Prof Maxime Breban | Prix du meilleur article de rechercher

Université de Versailles-Saint-Quentin, France

Author Profile

Scopus 

Early Academic Pursuits 🎓

Professor Breban embarked on his medical journey at Paris hospitals, earning his Doctor of Medicine (MD) degree between 1984 and 1990. His passion for immunology and rheumatology led him to pursue a Doctorate (PhD), which he completed in 1994 under the auspices of the French National Institute for Medical Research. During this period, he honed his expertise in immuno-rheumatology, laying a solid foundation for his future endeavors.igasconference.com

Professional Endeavors 🏥

Following his PhD, Professor Breban undertook a post-doctoral fellowship at the Harold Simmons Research Center, University of Texas, Dallas, USA, from 1990 to 1993, under the mentorship of Professor Joel D. Taurog. This international experience enriched his research perspective and expertise. Upon returning to France, he served as a clinical fellow and subsequently as Associate Professor of Immunology at Cochin Hospital, Paris, from 1993 to 2002. In 2002, he joined the Rheumatology Division of Ambroise Paré Hospital in Boulogne-Billancourt as a Professor of Rheumatology and ascended to the role of Head of the Department in 2011. Concurrently, he has been directing a research team focused on chronic inflammation in rheumatic disorders, which transitioned from the Cochin Institute to the Faculty of Simone Veil-Santé in 2013.igasconference.com

Contributions and Research Focus 🔬

Professor Breban’s research primarily centers on the immunogenetics of ankylosing spondylitis and related spondyloarthritis. He has been the principal investigator and coordinator for numerous clinical and basic research projects. Over the past two decades, he has contributed to over 100 original papers and 40 review articles in the field of SpA. His work has significantly advanced the understanding of the genetic and environmental factors contributing to SpA, including the role of the microbiome in disease pathogenesis.igasconference.com

Accolades and Recognition 🏆

Throughout his illustrious career, Professor Breban has received several prestigious awards, including the American College of Rheumatology Fellowship Award for Excellence in Scientific Research in 1992 and the Guillaumat-Piel Prize from the Foundation for Medical Research in 2018. These accolades underscore his substantial contributions to rheumatology research and his dedication to advancing medical science.igasconference.com

Impact and Influence 🌍

Professor Breban’s influence extends beyond his research contributions. He has played pivotal roles in various scientific committees and societies, including serving as President of the Scientific Committee of the French Rheumatology Society from 1998 to 2004 and as a member of the Scientific Board of the French National Research Agency from 2012 to 2013. His involvement in these organizations has shaped research agendas and fostered collaborations within the rheumatology community.

Legacy and Future Contributions 🚀

As a dedicated educator, Professor Breban has been imparting knowledge in rheumatology to medical students since 1993 and has been involved in various master’s programs and university diplomas related to immunology and rheumatology. His commitment to teaching ensures the cultivation of future generations of rheumatologists. Looking ahead, Professor Breban continues to lead research initiatives aimed at unraveling the complexities of chronic inflammatory diseases, with the goal of developing innovative therapeutic strategies and improving patient outcomes.

In summary, Professor Maxime Breban’s career is marked by a profound dedication to the study and treatment of rheumatic diseases. His extensive research, leadership roles, and commitment to education have left an indelible mark on the field of rheumatology, promising continued advancements in understanding and managing these complex conditions.

📝Notable Publications

Interleukin 17-producing C-C motif chemokine receptor 6 + conventional CD4+ T cells are arthritogenic in an animal model of spondyloarthritis


Authors: M. Beaufrère, Marie; M. Jacoutot, Manon; M.A. Breban, Maxime A.; S. Glatigny, Simon
Journal: Journal of Autoimmunity
Year: 2025

 Microbiota in spondyloarthritis: Where are we?

Authors: M.A. Breban, Maxime A.; M. Beaufrère, Marie; M. Jacoutot, Manon; S. Glatigny, Simon
Journal: Not provided
Year: Not provided

What is a severe axial spondyloarthritis?

Authors: F. Costantino, Félicie; M.A. Breban, Maxime A.; M.A. D’Agostino, Maria Antonietta
Journal: Not provided
Year: Not provided

 TGFβ signaling pathway is altered by HLA-B27 expression, resulting in pathogenic consequences relevant for spondyloarthritis

Authors: M. Lauraine, Marc; M. de Taffin de Tilques, Maxence; D. Melamed-Kadosh, Dganit; L.M. Araujo, Luiza M.; M.A. Breban, Maxime A.
Journal: Arthritis Research and Therapy
Year: 2024

Unmet needs in axial spondyloarthritis. Proceedings of the French spondyloarthritis taskforce workshop

Authors: D. Wendling, Daniel; M.A. Breban, Maxime A.; F. Costantino, Félicie; F.M. Verhoeven, Frank M.; C. Prati, Clément
Journal: Not provided
Year: Not provided